

N-(Indol-3-ylethyl)-2'-hydroxy-3'-methylpentanamide, a Novel Indole Derivative from *Xenorhabdus nematophilus*

Jianxiong Li,^{*,†,‡} Genhui Chen,[†] and John M. Webster^{†,‡}


Department of Biological Sciences, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada and Welichem Technology Corporation, 5551 Molina Road, North Vancouver, British Columbia V7R 4P3, Canada

Received April 15, 1996[®]

A new metabolite has been isolated for the first time from the culture broth of a symbiotic bacterium, *Xenorhabdus nematophilus*, and identified as *N*-(indol-3-ylethyl)-2-hydroxy-3-methylpentanamide (**1**) by spectroscopic methods.

Bacteria of the genus *Xenorhabdus* are known to exhibit antibacterial and antifungal activity^{1–3} and to be symbiotically associated with insect pathogenic nematodes of the genus *Steinernema*.^{4–6} Most species of *Xenorhabdus* exist in two phases, designated primary and secondary, when cultured *in vitro*. *Xenorhabdus* spp. primary phase, but not the secondary phase, produce metabolites that exhibit a wide spectrum of antibiotic activity.^{1–3,6} These metabolites, which are active against plant, animal, and human pathogenic bacteria and fungi,^{7,8} include indole derivatives, dithiopyrrolones (xenorhabdins), and benzopyran-1-one derivatives (xenocoumacins).^{7,8} Our continued interest in the metabolites of *Xenorhabdus* has led us to the discovery of a novel indole derivative from *X. nematophilus* strain BC1 (Enterobacteriaceae), and we report here its isolation and structural elucidation.

The culture broth was obtained by culturing *X. nematophilus* strain BC1 primary phase.² This broth was then subjected to solvent extraction with CH₂Cl₂ after removal of the cells by centrifugation. The CH₂Cl₂ extracts were concentrated and separated by Si gel chromatography with ethyl acetate:hexane (1:2) as eluent to give the novel compound **1**.



The presence of six low-field resonances observed between δ 7.05 and 8.04 in the ¹H NMR spectrum and eight resonances observed between δ 136.5 and 111.3 in the ¹³C NMR spectrum suggest the presence of a 3-indolyl substituent in **1**. Resonances at δ 0.87 (3 H, t, $J = 7.4$ Hz), 0.95 (3 H, d, $J = 6.7$ Hz), 1.82 (1 H, m), 1.32 (1 H, m), and 1.14 (1 H, m) indicated the presence of a CH₃CH(–R)CH₂CH₃ unit, which is consistent with the ¹H–¹³C 2D NMR spectrum. The (low- and high-resolution) MS of **1** showed a molecular ion at m/z 274 (C₁₆H₂₂N₂O₂) and the major principal daughter ion at m/z 143 (C₁₀H₉N), which further indicated the presence of an indole ring and suggested a –CH₂CH₂– unit

directly attached to the ring. The signals at δ 3.66 (2 H, q, $J = 6.8$ Hz) and 3.00 (2 H, td, $J = 6.8, 0.9$ Hz) in the ¹H NMR spectrum supported the assignment of a –CH₂CH₂XH– unit. The peak at δ 173.0 in its ¹³C NMR spectrum and the absorbance at 1654 cm^{–1} in the IR spectrum suggested the presence of a carbonyl group. The signals at δ 8.03 and 2.30 disappeared after the addition of D₂O, while the signal at δ 6.45 disappeared only after storage at room temperature for 2 days following the addition of D₂O. This suggested the presence of –OH and/or –NH groups (rapidly exchangeable protons) and a CONH group (slowly exchangeable proton), consistent with the strong absorbance at 3402 cm^{–1} in its IR spectrum. On the basis of the above analysis, the structure *N*-(indol-3-ylethyl)-2-hydroxy-3-methylpentanamide was assigned for the component **1**. This assignment is fully supported by the ¹H–¹³C 2D NMR spectrum that also allowed the assignment of the ¹H NMR and ¹³C NMR data. Further, the signals at δ 1.82 (H-3'), 1.32 (H-4'), and 1.14 (H-4') suggested that **1** is either the 3'*S*,2'*R* isomer or the 3'*R*,2'*S* isomer.⁹ As **1** appears to be derived from L-isoleucine, it is most likely to be *N*-(indol-3-ylethyl)-2'(*R*)-hydroxy-3'(*S*)-methylpentanamide. This is the first report of compound **1** from a natural source. Unlike the indole derivatives isolated previously from *Xenorhabdus*,⁷ **1** did not inhibit growth of the bacterium, *Bacillus subtilis*, when tested at a concentration of 100 μ g/mL.

In conclusion, a novel indole derivative (**1**) has been isolated and identified from *X. nematophilus* BC1. This is the first report of an indole derivative from this species of *Xenorhabdus*. This discovery further demonstrates the diversity of metabolites produced by the symbiotic bacteria, *Xenorhabdus* spp., and the potential of these bacteria as sources for lead chemicals for pharmaceuticals and agrochemicals.

Experimental Section

General Experimental Procedures. The NMR spectra, low-resolution MS, high-resolution MS, IR spectra, and HPLC analysis were performed on the same instruments as those described in an earlier paper on *Xenorhabdus* metabolites.⁷

Culture Conditions. *X. nematophilus* strain BC1 and its nematode symbiont *Steinernema feltiae* used in this study were collected from soil in British Columbia, Canada, and identified by Chen² and the bacterium deposited in the American Type Culture Collection (ATCC700168). The procedures and conditions for the

* Author to whom correspondence should be addressed. Tel.: (604) 291-5622. Fax: (604) 291-3496. E-mail: jli@sfu.ca.

[†] Department of Biological Sciences, Simon Fraser University.

[‡] Welichem Technology Corporation.

[®] Abstract published in *Advance ACS Abstracts*, November 15, 1996.

isolation, maintenance, and culture of the bacterium are the same as those described in an earlier paper.⁷

Extraction and Isolation. The cell-free material (3 L) was extracted with CH₂Cl₂ four times, and the combined extracts were dried with anhydrous Na₂SO₄ and filtered through glass wool. The filtrate was concentrated on a rotary evaporator below 30 °C under vacuum to yield a brown oil. The crude extracts were processed through a Si gel (200g Si gel 60, 40 × 5 cm, EM Science, Darmstadt, Germany) chromatographic column with 33% ethyl acetate in hexane as the eluent to give the major UV-detectable, solid metabolite **1** (7.4 mg): $[\alpha]^{25}_{\text{D}} -0.2^{\circ}$ (*c* 0.32, CHCl₃); EIMS (70 eV) *m/z* [M]⁺ 274 (5), 144 (17), 143 (100), 131 (6), 130 (47), 115 (4), 103 (3), 81 (2), 77 (6), 69 (6); HRMS 274.1676 (calcd for C₁₆H₂₂N₂O₂ 274.1681), 143.0740 (calcd for C₁₀H₉N 143.0735, 100); IR (KBr) ν_{max} 3402 (s), 2964, 1655, 1534, 1460, 744 cm⁻¹; ¹H NMR (CDCl₃) δ 8.03 (1 H, br s, NH), 7.62 (1 H, dd, *J* = 7.8, 1.0 Hz, H-4), 7.37 (1 H, dd, *J* = 8.4, 0.8 Hz, H-7), 7.22 (1 H, td, *J* = 8.1, 1.1 Hz, H-5), 7.13 (1 H, td, *J* = 7.9, 1.0 Hz, H-6) 7.05 (1 H, d, *J* = 2.3 Hz, H-2), 6.45 (1 H, m, CONH), 3.94 (1 H, t, *J* = 4.2 Hz, H-2'), 3.66 (2 H, q, *J* = 6.8 Hz, H-11), 3.00 (2 H, td,

J = 6.8, 0.9 Hz, H-10), 2.30 (1H, d, *J* = 5.2 Hz, OH), 1.82 (1 H, m, H-3'), 1.32 (1 H, m, H-4'), 1.14 (1 H, m, H-4'), 0.95 (3 H, d, *J* = 6.7 Hz, Me-3'), 0.87 (3 H, t, *J* = 7.4 Hz, H-5'); ¹³C NMR (CDCl₃) δ 173.0 (s, CO), 136.5 (s, C-9), 127.4 (s, C-8), 122.3 (d, C-5), 122.0 (d, C-2), 119.6 (d, C-6), 118.7 (d, C-4), 113.1 (s, C-3), 111.3 (d, C-7), 76.4 (d, C-2'), 39.4 (t, C-11), 38.9 (d, C-3'), 25.5 (t, C-10), 23.2 (t, C-4'), 15.5 (q, Me-3'), 11.8 (q, C-5').

References and Notes

- (1) Akhurst, J. *Gen. Microbiol.* **1982**, *128*, 3061–3065.
- (2) Chen, G.; Dunphy, G. B.; Webster, J. M. *Biol. Control* **1994**, *4*, 157–162.
- (3) Barbercheck, M.; Kaya, H. K. *J. Invertebr. Pathol.* **1990**, *55*, 225–234.
- (4) Thomas, G. M.; Poinar, G. O. *Int. J. Syst. Bacteriol.* **1979**, *29*, 352–360.
- (5) Akhurst, R. J. *Int. J. Syst. Bacteriol.* **1983**, *33*, 38–45.
- (6) Forst, S.; Nealon, K. *Microbiol. Rev.* **1996**, *60*, 21–43.
- (7) Li, J.; Chen, G.; Webster, J. M.; Czyzewska, E. *J. Nat. Prod.* **1995**, *58*, 1081–1086.
- (8) McInerney, B. V.; Taylor, W. C.; Lacey, M. J.; Akhurst, R. J.; Gregson, R. P. *J. Nat. Prod.* **1991**, *54*, 785–795.
- (9) Crombie, L.; Horsham, M. A.; Jarrett, S. R. M. *J. Chem. Soc., Perkin Trans. 1* **1991**, 1511–1524.

NP960396L